DURNE

TNF

Lunch & Check In

11:30 - 12:30 PM	Lunch & Check In
	Buffet Lunch (<i>Ballroom/Lounge</i>)

Speakers & Panelists

12:30 – 12:55 PM	Welcome & Introduction: State of Our Global Platform Banks Bourne (Founder & Chief Executive Officer, Bourne Partners)
1:00 – 1:15 PM	Strategic Capital Update Minor Hinson (<i>Chief Investment Officer, Bourne Partners Strategic Capital</i>)
1:20 – 1:35 PM	Market Update Jeremy Johnson (<i>Managing Director, Bourne Partners</i>)
1:40 – 2:10 PM	PAI: Differentiation and Transformation Moderator: Minor Hinson (Chief Investment Officer, Bourne Partners Strategic Capital) Speakers: Paul Campanelli (Senior Advisor, Bourne Partners & Board Member, PAI) Kurt Orlofski (Chief Executive Officer, PAI)
2:15 – 2:50 PM	Break #1
2:50 – 3:20 PM	Supply Chain Disruption Steve Scalia (President, Tanner Pharma Group)
3:25 – 4:05 PM	Private Equity Investing Today Moderator: Banks Bourne (Chief Executive Officer, Bourne Partners) Speaker: Brett Ingersoll (Senior Managing Director, Cerberus Capital Management)
4:10 – 4:45 PM	Break #2
4:45 – 5:05 PM	Current CDMO Landscape Amidst a Challenging Macro Environment Pat Walsh (Chairman & Chief Executive Officer, Alcami Corporation)
5:10 – 5:30 PM	Transforming a Company Nikhil Lalwani (<i>President & Chief Executive Officer, ANI Pharmaceuticals</i>)
5:35 – 5:55 PM	Dominating a Niche to Maximize Value Manny Soman (<i>Chief Executive Officer, Verista</i>)

Reception

6:00 – 7:00 PM	Networking Cocktail Reception
	Pavilion Terrace

Speaker Bios



Banks Bourne

Founder, Chief Executive Officer Bourne Partners

As Founder and CEO, Banks oversees all business operations and direct investment opportunities at Bourne Partners and Bourne Partners Strategic Capital. Under Banks' leadership, the firm has been party to more than \$10 billion of transactions in the Pharma, Pharma Services and Consumer Healthcare sectors having represented hundreds of closely held / entrepreneur led companies as well as those owned by many of the elite healthcare private equity funds. Banks got his start in Healthcare as

an early investor in King Pharmaceuticals. He followed that with an investment in commercial stage player Warner Chilcott and invested in / led the majority buyout, turnaround and subsequent sale of the Theramed Corporation headquartered in Canada. More recently, the Bourne Team and other partners co-founded Covis Pharma S.à.r.l. in 2011, successfully helping build the company through numerous product acquisitions and an eventual sale of the majority portion of the assets in 2015 for \$1.2 billion. As an investor, Banks remained involved with Covis which the team rebuilt to over \$100+ million in EBITDA and was sold to Apollo Global Management in 2020. In late 2015 the firm established Phoenix Therapeutics, Inc., a three-year joint venture with The Carlyle Group. Banks is the founder of Tanner Pharma Group, a pharma services company dedicated to providing managed access, commercialization and clinical trials services to patients and partners in more than 100 countries.

Currently, Banks is currently heavily involved in the firms' investments in PAI Pharma, a U.S. leader in generic liquid pharmaceuticals, and CadenceRx, a PBM focused in the workers compensation arena. He received a B.A. degree in Business Management from North Carolina State University and an M.B.A. from Wake Forest University. He is a member of Young Presidents Organization (YPO – Gold).

While Banks has derived great satisfaction by offering focused advisory services to, and investing in Pharma, Healthcare, and consumer-oriented companies that need strategic and operational insights; he is even more gratified by knowing that his work has helped companies to improve the health and well-being of patients across the world. He is passionate about providing healthcare and specifically pharmaceuticals to less fortunate patients, as demonstrated by supporting The Bourne Foundation, The Max Foundation and other non-profit organizations. In addition to his passion for a sub-80 round of golf and fresh ski powder, Banks enjoys traveling to new and interesting destinations and spending time with his wife (Molly) and children (Fairbanks and Mary Pope).

Speaker Bio



Minor Hinson

Senior Managing Director & Chief Investment Officer Bourne Partners Strategic Capital

Since starting at Bourne Partners in 2011, Minor has been responsible for direct investment activities and has been very involved in both the Phoenix Therapeutics, Inc. joint venture with The Carlyle Group, as well as with the creation, management, and asset disposition of Covis Pharma S.à.r.l ("Covis"). Minor also served on the U.S. Board of Covis from inception to exit and executed investments in AMRI (now Curia), WellDyne, Novitium, iNova,

Millicent Pharma, Cadence RX, American Injectibles as well as various fund investments.

Minor also serves on the Boards and lead the transaction teams on BPSC's investments in Pharmaceutical Associates Inc. and Carlin Consumer Health. Over the course of his career, Minor has been involved in over \$10 billion of financial transactions spanning the range of venture investing, private equity, mezzanine and senior debt, project finance debt and equity, cross boarder preferred stock issuances, sell-side and buy-side M&A transactions (both large cap and middle market), and other corporate finance advisory assignments.

Minor began his business career in 1984 in Corporate Banking at NationsBank/Bank of America and became a Senior Relationship Manager in the Baltimore/Washington loan production office before deciding to attend business school in 1990. After an M.B.A. internship in corporate finance at The Coca Cola Company in Atlanta, Minor accepted a position as an Associate at Bowles Hollowell Conner & Company in Charlotte. Minor returned to Bank of America in 2002 to join the Strategic Investment Group, a group he eventually managed. He was then recruited to manage Corporate Development for the bank's Global Treasury Services (\$4 billion in profit). In 2007, Minor accepted a position to join Christofferson Robb & Company to raise capital and work on the initial London project team of the firm's 300 MW offshore wind farm (Thanet Offshore Wind Limited) which, when opened, was the world's largest offshore wind project.

Minor received a B.A. in Economics from Davidson College in 1984, as well as an M.B.A. (honor society) in 1992 from The Kenan-Flagler Business School at UNC Chapel Hill. Most importantly, Minor has been married to his wife Tiffany over 24 years and is the father of two Children – Minor (college) and Sara Frances (high school).

Speaker Bios



Jeremy Johnson Managing Director

Bourne Partners

Jeremy has over 20 years of healthcare-focused M&A and private equity experience. He has been with Bourne Partners since 2006 and is part of the of the core leadership team at the firm. Jeremy currently serves as a Managing Director, overseeing the broker dealer and all Investment Banking activities.

Prior to Bourne Partners, Jeremy was a founding member and Managing

Director at Madison Keats, a life sciences strategy and consulting firm. Jeremy began his career at VentureWorx, an Internet incubator. He is a graduate of Georgetown University where he earned a bachelor of arts in Economics.

Outside of work, Jeremy is active in the community. He is a member of Leadership Charlotte and an avid supporter of a few personally important charitable foundations. In addition, he remains very active with Georgetown and is President of the local alumni club.

Jeremy is a native of North Carolina and currently lives in the same neighborhood in south Charlotte where he grew up. He is married to his wife, Jessica, and they have three young children, with whom he is happy to spend most of his free time.

Speaker Bios



Paul Campanelli

Senior Advisor Bourne Partners

In May 2021, Paul Campanelli was appointed as a senior advisor to Bourne Partners.

Paul is the former Chairman, President, Chief Executive Officer and Director of Endo International with over 30 years of experience. Paul transformed the organization into an industry-leading generics business and built a strong leadership team with a vision of becoming a highly focused generics

and specialty branded pharmaceutical company. Endo delivers quality medicines to patients in need through excellence in development, manufacturing, and commercialization in multiple business segments including U.S. Branded Pharmaceuticals, U.S. Branded Sterile Injectables, U.S. Generic Pharmaceuticals, and International Pharmaceuticals.

Paul's leadership drove the company to significantly increased total revenue. During his tenure, Par and Endo acquired Michigan-based JHP Pharmaceuticals, established a business office in London to serve as Par's entry point into the European generics market and completed its acquisition of an active pharmaceutical ingredients (API) facility located in Chennai, India. Paul also shaped the company's strategic focus on organic growth through investments in hard-to-produce generic assets and technologies, a highly specialized branded business, and a concentration on differentiated and intelligent product selection.

Earlier in his tenure, Paul served as Chief Operating Officer of Par Pharmaceutical prior to taking on the role of President and Chief Executive Officer. Mr. Campanelli also held roles of increasing responsibility, including President of Par Pharmaceutical, Inc., the company's generics division, from 2011 to 2012 and Executive Vice President, Business Development & Licensing; Executive Vice President and President of Par Pharmaceutical, Inc.; and was named a Corporate Officer by Par's board of directors. He served on the board of directors of Sky Growth Holdings Corporation.

Paul currently serves on the board of directors for PAI (Pharmaceutical Associates Inc.), Slayback Pharma and Convey Health Solutions. Paul previously served on the board of Sky Growth Holdings, a TPG company.

Speaker Bios



Steve Scalia

President Tanner Pharma Group

Steve Scalia is the President of Tanner Pharma Group, a 20-year-old specialist pharmaceutical services provider headquartered in Charlotte, NC USA with offices in the United Kingdom, Brazil, Switzerland, and Ireland. Tanner provides a portfolio of service offerings focused on improving global access to medicines worldwide.

In his role, Steve leads the company's business activities with oversight

of the commercial divisions, cross-functional departments, the Corporate Governance Team, and the Senior Management Team. Prior to joining Tanner Pharma in 2011, Steve founded three start-ups that included complex operating models and custom facilities requiring real estate development. Steve began his career in the pharmaceutical industry, holding sales and management positions at Upjohn Pharmaceuticals and Pharmacia Corp.



Kurt Orlofski

Chief Executive Officer Pharmaceutical Association Inc. (PAI)

Kurt Orlofski has served as CEO of Pharmaceutical Associates Inc. since January 2017. A leader and turnaround CEO, Kurt has led generic pharmaceutical companies for over 20 years.

From 2009 to 2016, he was President and COO of G&W Laboratories. Prior to G&W, he was President of Wockhardt USA (Apr 2007 - Aug 2009). Prior to his time with Wockhardt, he was President and Chief Executive Officer

of Pliva, the US subsidiary of global specialty pharmaceutical company Pliva. He was responsible for all Pliva US businesses including USD300m of generics business. Previously, Mr. Orlofski was Senior Vice President of Global Business Development at Alpharma Human Pharmaceuticals.

His areas of expertise include pharmaceutical general management, transformational leadership, operations and quality management, sales and marketing in generics, new business unit start-ups, product acquisition, brand and generic in and out licensing of products and technology, business unit and asset sales and acquisitions (including integration), contract manufacturing deals in and out, and negotiation and execution of supplier and customer supply agreements.

Speaker Bios



W. Brett Ingersoll

Chairman of the Private Equity Investment Committee and Senior Managing Director *Cerberus Capital Managment*

Mr. Ingersoll is Chairman of the Cerberus Private Equity Investment Committee and a Senior Managing Director. From 2005 to 2021, he served as the Global Co-Head or Head of the firms Global Private Equity practice and during his 20 year tenure at Cerberus, has been central in leading the Firm's Private Equity platform. Mr. Ingersoll has led all the firm's private equity investments in healthcare services, pharma services and pharma

sectors and in addition has led numerous other investments in the business services, financial services, aviation and industrials sectors. Over his 30 year career in private equity, Mr Ingersoll has served on over 35 private and public corporate boards of directors including over 20 Cerberus portfolio companies and currently is a member of the boards of World Wide Flight Services (WFS) and Alzheimer's Research and Treatment Centers (ARTC).

Prior to joining Cerberus, he was a General Partner and a member of the Investment Committee at JPMorgan Partners, now renamed CCMP Capital, for nine years. Mr. Ingersoll began his professional career at Goldman Sachs & Co. after graduating from Brigham Young University (BYU). After Goldman Sachs, Mr. Ingersoll an M.B.A. from Harvard Business School. Mr. Ingersoll currently serves as a member of the National Advisory Council at BYU's Marriott School of Management. Mr. Ingersoll and his wife Jennifer have been married for 32 years, have lived in New York City for 30 years, and are the proud parents of three adult children, Jordan (27), Ethan (24) and Cleo (21).

Speaker Bios



Pat Walsh

Chairman, Chief Executive Officer Alcami Corporation

Pat Walsh has been CEO of six high growth organizations over the course of a distinguished 40 year career in the pharmaceutical industry. Prior to Alcami, he was co-founder and CEO of TriPharm Services, a parenteral manufacturing business acquired by Alcami. From 2015 to 2019, Mr. Walsh was the CEO of Avista Pharma Solutions, a PE-backed CDMO acquired by Cambrex. Pat was named CEO of PE-backed AAIPharma Services in 2010 and led the company through an impressive growth trajectory, culminating in the

sale of the company in 2014. Prior executive roles also include CEO of Kadmus Pharma (acquired by Organon) and President and COO of Gensia-Sicor (acquired by Teva).

In addition to his duties at Alcami, Pat serves as Chairman of the Board of specialty pharma company ANI Pharmaceuticals (NASDAQ: ANIP) and an independent director of private equity backed Institute Chemica Emiliano (I.C.E.) based in Milan Italy. Pat also serves as an Operating Partner at healthcare PE firm Ampersand Capital. Prior board of director roles include: Chairman of Brammer Bio, an independent director at Landec Corp (NASDAQ: LNDC), MedPharm Ltd, Avid BioServices (NASDAQ: CDMO) and numerous other pharma and biotechnology companies over the course of his career.



Speaker Bios



Nikhil Lalwani

President, Chief Executive Officer ANI Pharmaceuticals

Nikhil Lalwani is the President and Chief Executive Officer of ANI Pharmaceuticals (NASDAQ: ANIP) and a member of ANI's Board of Directors. He is driving the transformation of ANI into a diversified biopharmaceuticals company serving patients in need and delivering sustainable growth. . Prior to joining ANI in September 2020, Nikhil worked at Cipla Ltd (NSE: CIPLA), a global pharmaceutical company where he successfully led multiple businesses, including as CEO of Cipla India Rx, CEO of Cipla USA,

CEO of InvaGen and Head of Cipla's Global Respiratory business. Prior to Cipla, Mr. Lalwani was an Associate Partner with McKinsey & Company serving pharmaceutical and healthcare companies across the world, and an engineer with Medtronic. Mr. Lalwani holds a B.S. in Electrical Engineering from Georgia Institute of Technology and an M.B.A. from the Wharton School at the University of Pennsylvania.



Manny Soman Chief Executive Officer

Verista

Manny has a proven track record of growing and building successful global businesses and practices. He has more than 30 years of leadership experience, encompassing Life Science services, IT/Systems consulting services, and technology innovations. Prior to joining Verista, Manny was President & CEO of Sciformix that was acquired by Labcorp, Operations Leader of HP in EMEA region, COO of Patni Computers, Global IT Business Leader for Genpact and MD & CEO of Deloitte, India. He has worked in

several regions across the world, including the US, Europe, India and the Far East.